Erratum: Geographical differences associated with SNPs in nine gene targets among resistant clinical isolates of mycobacterium tuberculosis (Journal of Clinical Microbiology (2013) DOI: 10.1128/JCM.00857-13);Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of mycobacterium tuberculosis

Journal of Clinical Microbiology

Volumn 52, Issue 5, 2014, Pages 1322-1329

  Hoshide, Matt ^a   Qian, Lishi ^a   Rodrigues, Camilla ^b   Warren, Rob ^c   Victor, Tommie ^c   Evasco II, Henry B ^d   Tupasi, Thelma ^d   Crudu, Valeriu ^e   Douglas, James T ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b P D HINDUJA NATIONAL HOSPITAL   (India)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d Tropical Disease Foundation Inc   (Philippines)

^e Center for Health Policies and Studies   (Moldova)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

AHPC PROMOTER GENE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA EXTRACTION; EIS PROMOTER GENE; GENE MUTATION; GENE TARGETING; GEOGRAPHIC DISTRIBUTION; GYRA GENE; GYRB GENE; INDIA; INHA PROMOTER GENE; KATG GENE; MOLDOVA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PHILIPPINES; PRIORITY JOURNAL; PROMOTER REGION; RPOB GENE; RRS GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICA; TLYA GENE; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; PROCEDURES; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; DNA, BACTERIAL; GENES, BACTERIAL; INDIA; MICROBIAL SENSITIVITY TESTS; MOLDOVA; MYCOBACTERIUM TUBERCULOSIS; PHILIPPINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SOUTH AFRICA; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84899567679     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02478-13     Document Type: Erratum

References (20)

1. World Health Organization. 2001. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-plus. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/2001/WHO-CDS-TB- 2001.288.pdf.
2. World Health Organization. 2011. Multidrug-resistant tuberculosis: update 2011. World Health Organization, Geneva, Switzerland. http://www.stoptb.org/wg/ mdrtb/assets/documents/MDR-tuberculosis-2011 update.pptx.
3. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. 2008. Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 177:787-792. http://dx.doi.org/10.1164/rccm.200709-1436OC.
4. Evans CA. 2011. GeneXpert: a game changer for tuberculosis control? PLoS Med. 8:e1001064. http://dx.doi.org/10.1371/journal.pmed.1001064.
5. Sangren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. Tuberculosis drug resistance mutation database. PLoS Med. 6:e1000002. http://dx.doi.org/10.1371/journal.pmed.1000002.
6. Riska PF, Jacobs WR, Jr, Alland D. 2000. Molecular determinants of drug resistance in tuberculosis. Int. J. Tuberc. Lung Dis. 4(Suppl 1):S4-S10.
7. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T. 1993. Detection of rifampicinresistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650.
8. Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:3-29.
9. Maus CE, Plikaytis BB, Shinnick TM. 2005. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:571-577. http://dx.doi.org/10.1128/AAC.49.2.571-577.2005.
10. Zaunbrecher MA, Sikes RD, Jr, Metchock B, Shinnick TM, Posey JE. 2009. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 106:20004-20009. http://dx.doi.org/10.1073/pnas.0907925106.
11. World Health Organization. 2010. Treatment of tuberculosis guidelines, 4th ed. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who. int/publications/2010/9789241547833-eng.pdf.
12. Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME. 2011. Size and usage patterns of private TB drug markets in high burden countries. PLoS One 6:e18964. http://dx.doi.org/10.1371/journal.pone.0018964.
13. Luo T, Zhao M, Li Z, Xu P, Gui X, Pickerill S, DeRiemer K, Mei J, Gao Q. 2010. Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob. Agents Chemother. 54:1075-1081. http://dx.doi.org/10.1128/AAC.00964-09.
14. Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H. 2010. Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi region of India. Antimicrob. Agents Chemother. 54:4789-4793. http://dx.doi.org/10.1128/AAC.00661-10.
15. Ma X, Wang H, Deng Y, Liu Z, Xu Y, Pan X, Musser J, Graviss EA. 2006. rpoB gene mutations and molecular characterization of rifampinresistant Mycobacterium tuberculosis isolates from Shandong Province, China. J. Clin. Microbiol. 44:3409-3412. http://dx.doi.org/10.1128/JCM.00515-06.
16. Ohno H, Koga H, Kohno S, Tashiro T, Hara K. 1996. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob. Agents Chemother. 40:1053-1056.
17. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc. Natl. Acad. Sci. U. S. A. 94:9869-9874.
18. Engström A, Perskvist N, Werngren J, Hoffner SE, Juréen P. 2011. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 66:1247-1254. http://dx.doi.org/10.1093/jac/dkr109.
19. Gupta AK, Reddy VP, Lavania M, Chauhan DS, Venkatesan K, Sharma VD, Tyagi AK, Katoch VM. 2010. jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol. Indian J. Med. Res. 132:176-188.
20. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184:269-276. http://dx.doi.org/10.1164/rccm.201011-1924OC.